Clinical Trials: Laboratory Data Reconciliation

Regulatory Audit Findings Related to Data Reconciliation in Lab and EDC Systems

Posted on digi By digi

In recent years, global regulatory bodies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and MHRA have intensified their scrutiny of data reconciliation practices in clinical trials. The reconciliation process—ensuring that laboratory data matches with entries in the Electronic Data Capture (EDC) system—is critical to upholding data integrity. Discrepancies between the lab and clinical data records not only risk misleading results but also violate Good Clinical Practice (GCP) guidelines.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

CAPA Playbook – Root Causes of Reconciliation Failures in Clinical Trials

Posted on digi By digi

Clinical trial success hinges on reliable data. One critical area often overlooked is the reconciliation of laboratory data with the Electronic Data Capture (EDC) system. Regulatory bodies such as the FDA, EMA, and PMDA have repeatedly identified data reconciliation failures as significant Good Clinical Practice (GCP) non-compliance during inspections.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Data Management SOPs for Managing Reconciliation Cycles in Global Trials

Posted on digi By digi

Data reconciliation between laboratory systems and electronic data capture (EDC) platforms is a critical step in ensuring data integrity in clinical trials. In multi-country trials, the complexity of managing disparate systems, languages, and regulations makes reconciliation even more challenging. As such, the establishment of robust, inspection-ready Standard Operating Procedures (SOPs) for reconciliation cycles is essential to avoid regulatory scrutiny and ensure accurate trial reporting.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Quality Oversight of Reconciliation Vendors: What Sponsors Must Check

Posted on digi By digi

As clinical trials scale across multiple countries and data sources, many sponsors outsource critical functions such as laboratory data reconciliation to specialized vendors or CROs. These vendors handle harmonization of data from EDC systems, laboratories, and central databases. However, outsourcing does not absolve sponsors of their responsibility for data quality and regulatory compliance.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Case Studies on Cross-Functional Reconciliation Oversight and CAPA Solutions

Posted on digi By digi

As clinical trials become increasingly complex, reconciliation of laboratory and EDC data is no longer a task that can be confined to data management alone. The interdependencies between the clinical team, vendors, quality assurance (QA), and data management require structured cross-functional oversight to identify, resolve, and prevent discrepancies.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

How to Conduct Reconciliation Root Cause Analysis – FDA-Ready Guide

Posted on digi By digi

In clinical trials, reconciliation between laboratory data and EDC (Electronic Data Capture) systems ensures the accuracy, completeness, and consistency of safety-critical information. However, discrepancies often arise due to system mismatches, human error, protocol deviations, or vendor process gaps. These errors, if not effectively investigated, can lead to repeat findings during audits and inspections.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Deviation Handling in Reconciliation Activities – Inspection Readiness Guide

Posted on digi By digi

In the context of clinical trials, laboratory data must be accurately and consistently reconciled with the corresponding records in the Electronic Data Capture (EDC) system. Any inconsistencies—whether due to human error, system misconfiguration, or protocol deviations—must be carefully managed. When these inconsistencies meet predefined thresholds or impact data quality or subject safety, they are classified as “deviations.”

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Case Studies on Query Management During Reconciliation Cycles

Posted on digi By digi

Laboratory and EDC reconciliation is a vital quality assurance function in clinical trials. One of the key outputs of reconciliation cycles is the generation of queries—requests for clarification or correction of discrepancies between laboratory data and the data captured in the Electronic Data Capture (EDC) system. These queries can stem from inconsistencies in subject ID, visit date, test values, units, or missing results.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation

Reconciliation SOPs – Must-Have Elements for Regulatory Compliance

Posted on digi By digi

Standard Operating Procedures (SOPs) play a foundational role in laboratory and EDC data reconciliation across clinical trials. They define standardized workflows, roles and responsibilities, escalation criteria, reconciliation intervals, documentation controls, and corrective actions. In audits conducted by FDA and EMA, reconciliation SOPs are reviewed to ensure they are risk-based, traceable, and compliant with Good Clinical Practice (GCP) and ALCOA+ principles.

Click to read the full article.

Laboratory and Sample Management, Laboratory Data Reconciliation